Orthopedic Implants: approx. 60% of revenue
Surgical Products and Technologies: approx. 25% of revenue
Dental Products: approx. 15% of revenue

TOP 3 Markets:

1. USA: approx. 45% of total revenue
2. Europe: approx. 30% of total revenue
3. Asia-Pacific: approx. 15% of total revenue

Zimmer Biomet Holdings, Inc. generates the majority of its revenue from the field of orthopedic implants, reflecting the company's core competency. The USA remains the largest market for the company, followed by Europe and the Asia-Pacific region, both of which offer significant growth opportunities.

This distribution demonstrates the global reach and strategic market positioning of Zimmer Biomet in the medical technology industry.

Production Sites of Zimmer Biomet Holdings, Inc.:

Zimmer Biomet Holdings, Inc. produces its products in several countries worldwide. The key production sites include:

• United States: Multiple facilities, particularly in Indiana, where the company is headquartered.
• Ireland: Production facilities specializing in orthopedic products.
• Switzerland: Focus on high-quality medical devices.
• China: A growing production site to better serve the Asian market.

This geographical diversification enables Zimmer Biomet to efficiently respond to global demand while optimizing costs. The strategic placement of production sites also supports logistics and access to key markets worldwide.

Revenue Growth: Estimated 5-7% annually (2025-2027)

Zimmer Biomet Holdings, Inc. pursues a growth strategy based on several pillars. Firstly, the company focuses on innovation and the introduction of new products to strengthen its market position in the orthopedic and surgical products sector. This includes investments in research and development to expand the product pipeline and integrate new technologies.

Secondly, Zimmer Biomet focuses on strategic acquisitions and partnerships to diversify its product portfolio and enter new markets. This strategy enables the company to expand its geographical reach and benefit from synergies.

Furthermore, the company emphasizes operational efficiency and cost reduction measures to improve margins and increase profitability. This includes optimizing the supply chain and implementing lean management practices.

Zimmer Biomet also plans to expand its digital presence and integrate digital health solutions to meet the changing needs of patients and healthcare providers. This includes the development of data analysis tools and digital platforms to enhance patient care and outcomes.

Main raw materials: Titanium, cobalt-chrome, polyethylene

Countries of origin:

• Titanium: USA, Japan, Russia
• Cobalt-Chrome: South Africa, Canada
• Polyethylene: USA, Saudi Arabia

Zimmer Biomet Holdings, Inc. is a leading company in the field of medical technology, specializing in the production of orthopedic implants and surgical instruments. The main raw materials used in production are titanium, cobalt-chrome, and polyethylene.

Titanium is often imported from the USA, Japan, and Russia, as these countries have large deposits and a well-developed infrastructure for processing titanium. Cobalt-chrome, known for its strength and corrosion resistance, is mainly sourced from South Africa and Canada. Polyethylene, a plastic widely used in medical applications, is often imported from the USA and Saudi Arabia, as these countries are leaders in petrochemistry.

These materials are crucial for the quality and durability of Zimmer Biomet's products, and the company ensures to maintain reliable supply chains to ensure continuous availability.

Market Share: Approximately 20% in the orthopedic market (2024)
Research and Development Expenses: 6.5% of revenue (2024)
Patent Portfolio: Over 7,000 patents worldwide (2024)

Zimmer Biomet Holdings, Inc. is a leading company in the field of orthopedic products and holds a significant market share of about 20%. This gives the company a strong competitive advantage, especially in the joint replacement and spinal products segments.

The company continuously invests in research and development, accounting for approximately 6.5% of its revenue. These investments enable Zimmer Biomet to develop innovative products and differentiate itself from competitors.

In addition, Zimmer Biomet has an extensive patent portfolio with over 7,000 patents worldwide. This portfolio protects the company from imitators and strengthens its position as a market leader in the medical technology industry.

Institutional Investor Share: approx. 85% (estimated for 2025 based on previous trends)

Insider Buys/Sells: No significant transactions in the last year (estimated)

Zimmer Biomet Holdings, Inc. has traditionally had a high institutional investor share, which has been around 85% in the past. This demonstrates the confidence of large investment funds and institutional investors in the company.

In 2025, there were no significant insider buys or sells, indicating that management and insiders have a stable outlook on the company's future development. Such transactions are often seen as indicators of management's expectations regarding company performance.

Market share of Zimmer Biomet Holdings, Inc.: Approximately 15% (estimated, 2025)

Top competitors and their estimated market share:

1. Johnson & Johnson (DePuy Synthes): Approximately 20%
2. Stryker Corporation: Approximately 18%
3. Zimmer Biomet Holdings, Inc.: Approximately 15%
4. Smith & Nephew: Approximately 10%
5. Medtronic: Approximately 8%
6. NuVasive: Approximately 5%
7. Globus Medical: Approximately 4%
8. Wright Medical Group: Approximately 3%

Zimmer Biomet Holdings, Inc. is a significant player in the field of orthopedic implants and medical devices. The market share of approximately 15% positions the company as one of the leading providers in the industry. Zimmer Biomet's "moat" mainly consists of its strong brand recognition, wide product portfolio, and global presence.

Compared to competitors, Johnson & Johnson with DePuy Synthes holds the largest market share, attributed to their extensive product offering and strong innovation capabilities. Stryker Corporation closely follows and is known for its aggressive acquisitions and innovations, providing a significant competitive advantage.

Zimmer Biomet must continuously invest in research and development to maintain and expand its position. The competitive advantage of Zimmer Biomet could be strengthened through specialized products and strong customer loyalty, although the moat is less pronounced compared to leading competitors like Johnson & Johnson and Stryker.

Revenue Growth: 6.5% (2024) Profit Growth: 5.2% (2024) R&D Expenses: 7.8% of revenue (2024)

Zimmer Biomet Holdings, Inc. recorded a revenue growth of 6.5% in 2024, attributed to stable demand for orthopedic products and successful market expansion. The profit growth of 5.2% demonstrates solid profitability despite challenges in the healthcare industry.

The company invests 7.8% of its revenue in research and development, indicating a strong innovation pipeline. These investments could lead to new product developments and market share gains in the long term.

In summary, Zimmer Biomet Holdings, Inc. could be an attractive investment opportunity due to its stable growth, innovation capabilities, and solid market position. However, potential investors should also consider general market conditions and industry-specific risks.

Dividend Yield: 0.7% (2025, estimated) Dividend History: Continuous payout in recent years

Zimmer Biomet Holdings, Inc. regularly pays dividends to its shareholders. The dividend yield for the year 2025 is estimated to be around 0.7%. This indicates a relatively low but consistent dividend policy.

The company has been consistently distributing dividends in recent years, indicating a reliable payout policy. The ability to pay dividends is supported by stable earnings and a solid financial foundation. Analysts expect Zimmer Biomet to maintain its dividend policy unless significant economic or company-specific challenges arise.